Clovis Oncology, Inc.
CLVS
|
$0.0812
-3.94%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (26.22% volume)
Earnings Calendar: 2023-02-22
Market Cap: $ 11,770,367
http://www.clovisoncology.com
Sec Filling | Patents | 484 employees
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
acquisitions cancer prostate cancer liver treatment cancer treatments
Drugs
Rubraca (rucaparib)add to watch list Paper trade email alert is off
Amryt Pharma plc
AMYT
|
$14.7
0.0%
2.4M
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (-0.2% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 940,255,350
http://amrytpharma.com
Sec Filling | Patents | n/a employees
Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. It operates through the following segments: Commercial, Research and Development. The Commercial segment includes the financial results of the Group's two current commercial product lines, Imlan and Lojuxta. The Research and Development segment comprises the financial results of the Group’s two current research and development assets, AP101 and AP102. The company was founded by Joseph Amrit Wiley and Rory Peter Nealon on August 28, 2015 and is headquartered in Dublin, Ireland.
treatment
Drugs
Juxtapid (lomitapide mesylate)Myalept (metreleptin)
add to watch list Paper trade email alert is off
Apollo Endosurgery, Inc.
APEN
|
$10.0
0.75%
1.7M
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-53.84% volume)
Earnings Calendar: 2023-05-02
Market Cap: $ 579,719,190
http://apolloendo.com
Sec Filling | Patents | 217 employees
Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, OverStitch Sx Endoscopic Suturing System, and Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas; inadvertent perforation of the GI tract; tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon; the treatment of swallowing disorders; esophageal stent fixation and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.
gastrointestinal endoscopy treatment
add to watch list Paper trade email alert is off
Athenex, Inc.
ATNX
|
$0.2031
-7.78%
1.9M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-86.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (199.02% volume)
Earnings Calendar: 2022-10-27
Market Cap: $ 1,759,498
http://www.athenex.com
Sec Filling | Patents | 574 employees
(US) Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves in the sales and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.
cancer tirbanibulin treatment
add to watch list Paper trade email alert is off
Entasis Therapeutics Holdings Inc.
ETTX
|
$2.19
-0.46%
0.46%
|
Health Technology
(0.0% 1d) (-0.2% 1m) (0.0% 1y) (-0.2% 2d) (0.2% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2022-08-03
Market Cap: $ 104,795,396
http://www.entasistx.com
Sec Filling | Patents | 47 employees
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.
batteries battery msa antibacterial injection
add to watch list Paper trade email alert is off
Global Blood Therapeutics, Inc.
GBT
|
$68.49
0.02%
-0.02%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (73.96% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 4,621,443,500
http://www.gbt.com
Sec Filling | Patents | 352 employees
(US) Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.
t-cell ceiling
Drugs
OXBRYTA (Voxelotor)add to watch list Paper trade email alert is off
ABIOMED, Inc.
ABMD
|
$381.02
0.06%
0.07%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (758.37% volume)
Earnings Calendar: 2023-02-02
Market Cap: $ 17,180,642,928
http://www.abiomed.com
Sec Filling | Patents | 1536 employees
(US) ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA.
heart brands
add to watch list Paper trade email alert is off
Aerie Pharmaceuticals, Inc.
AERI
|
$15.25
0.0%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (13.48% volume)
Earnings Calendar: 2023-02-23
Market Cap: $ 753,615,457
http://www.aeriepharma.com
Sec Filling | Patents | 380 employees
(US) Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.
eye treatment
Drugs
Rhopressa (netarsudil)Rocklatan (netarsudil and latanoprost ophthalmic solution, 0.02%/0.005%)
add to watch list Paper trade email alert is off
ConforMIS, Inc.
CFMS
|
$2.26
0.44%
0
|
Health Technology
(0.0% 1d) (0.4% 1m) (41.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 17,803,134
http://www.conformis.com
Sec Filling | Patents | 271 employees
ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States; Germany; and Rest of the World. The firm's products include iUni, iDuo, iTotal CR, and iTotal. The company was founded by Philipp Lang in 2004 and is headquartered in Billerica, MA.
add to watch list Paper trade email alert is off
Zynerba Pharmaceuticals, Inc.
ZYNE
|
$1.3
3.08%
860K
|
Health Technology
(0.0% 1d) (0.0% 1m) (223.8% 1y) (0.0% 2d) (0.0% 3d) (2.4% 7d) (13.41% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 70,121,260
http://www.zynerba.com
Sec Filling | Patents | 28 employees
(US) Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. It offers Zygel product which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.
neuropsychiatric msa
add to watch list Paper trade email alert is off
NuVasive, Inc.
NUVA
|
$39.75
-2.24%
-2.29%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (-8.0% 1y) (0.0% 2d) (-2.2% 3d) (0.0% 7d) (156.26% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 2,084,854,388
http://www.nuvasive.com
Sec Filling | Patents | 2800 employees
(US) NuVasive, Inc. engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.
add to watch list Paper trade email alert is off
IntriCon Corporation
IIN
|
$24.24
0.04%
0.04%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (40.43% volume)
Earnings Calendar: 2022-08-08
Market Cap:
http://www.intricon.com
Sec Filling | Patents | 780 employees
Intricon Corp. engages in the design, development, engineering, manufacture, and distribution of miniature and micro-miniature body-worn devices. It operates through the Body-Worn Device and Hearing Health Direct-To-End Consumer segments. The Body-Worn Device segment comprises medical, hearing health, and professional audio markets. The Hearing Health Direct-To-End Consumer segment provides advanced hearing products such as ultra-miniature volume controls and trimmers, custom amplifiers, and custom, completed hearing instruments. The company was founded in 1930 and is headquartered in Arden Hills, MN.
audio
add to watch list Paper trade email alert is off
IVERIC bio, Inc.
ISEE
|
$39.95
0.38%
0.38%
0
|
Health Technology
(0.0% 1d) (0.2% 1m) (37.9% 1y) (0.2% 2d) (0.6% 3d) (0.0% 7d) (-41.69% volume)
Earnings Calendar: 2023-08-01
Market Cap: $ 5,504,420,783
http://www.ivericbio.com
Sec Filling | Patents | 38 employees
IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.
gene therapies
add to watch list Paper trade email alert is off
La Jolla Pharmaceutical Company
LJPC
|
$6.22
0.0%
|
Health Technology
(0.0% 1d) (-0.2% 1m) (0.0% 1y) (0.0% 2d) (0.8% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 155,107,412
http://www.lajollapharmaceutical.com
Sec Filling | Patents | 91 employees
(US) La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla’s investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.
hormone msa treatment
Drugs
Giapreza (angiotensin II)add to watch list Paper trade email alert is off
Surface Oncology, Inc.
SURF
|
$1.07
-0.93%
-1.41%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (60.8% 1y) (0.0% 2d) (-0.9% 3d) (0.0% 7d) (78.2% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 65,082,187
http://www.surfaceoncology.com
Sec Filling | Patents | 49 employees
(US) Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388); a clinical-stage collaboration with Novartis targeting CD73 (NZV930); and two preclinical programs, each focused primarily on activating natural killer or depleting regulatory T cells. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.
cancer t-cell cd73 msa ceiling
add to watch list Paper trade email alert is off
Surgalign Holdings, Inc.
SRGA
|
$0.1829
-50.36%
8.7M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-78.0% 1y) (0.0% 2d) (-9.1% 3d) (0.0% 7d) (-54.59% volume)
Earnings Calendar: 2023-08-08
Market Cap: $ 1,690,130
http://www.surgalign.com
Sec Filling | Patents | 935 employees
Surgalign Holdings, Inc. is a global medical technology company, which engages in designing, developing and manufacturing biologic metal and synthetic implants worldwide. It focuses on delivering spine solutions that drive clinical and economic outcomes. The company markets its products throughout the United States and other countries worldwide through an expanding network of independent distributors. The company was founded in February 1998 and is headquartered in Deerfield, IL.
add to watch list Paper trade email alert is off
Turning Point Therapeutics, Inc.
TPTX
|
$76.01
-0.03%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (NaN% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 3,806,145,795
http://www.tptherapeutics.com
Sec Filling | Patents | 95 employees
Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.
cancer
add to watch list Paper trade email alert is off
Horizon Therapeutics Public Limited Company
HZNP
|
$116.3
0.03%
29M
|
Health Technology
(0.0% 1d) (0.0% 1m) (4.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (383.01% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 26,632,068,258
http://www.horizontherapeutics.com
Sec Filling | Patents | 1200 employees
Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.
add to watch list Paper trade email alert is off
Invacare Corporation
IVC
|
$0.6598
-19.67%
0
|
Health Technology
(0.0% 1d) (-1.4% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (-1.4% 7d) (NaN% volume)
Earnings Calendar: 2023-02-15
Market Cap: $ 24,910,310
http://www.invacare.com
Sec Filling | Patents | 3900 employees
(US) Invacare Corp. engages in the manufacture and distribution of medical equipment used in non-acute care settings. It focuses on medical device solutions for congenital, acquired, and degenerative ailments. The firm operates through the following segments: North America and Europe. The company was founded by Aaron Malachi Mixon III in 1979 and is headquartered in Elyria, OH.
add to watch list Paper trade email alert is off
Vapotherm, Inc.
VAPO
|
$1.27
-37.0%
13K
|
Health Technology
(0.0% 1d) (0.0% 1m) (135.7% 1y) (0.0% 2d) (6.7% 3d) (0.0% 7d) (-18.04% volume)
Earnings Calendar:
Market Cap: $ 7,795,683
http://www.vapotherm.com
Sec Filling | Patents | 284 employees
(US) Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. Its products include Precision Flow, Precision Flow Heliox, Oxygen Assist Module, Nitric Oxidie Disposable Patient Circuit, Tracheostomy Adapter, and Aerogen Adapter. The company was founded by William F. Niland, Jun Cortez, and William Cirksena in 1998 and is headquartered in Exeter, NH.
respiratory
add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10